Siguan points-based acupuncture treatment for migraine: A systematic review with meta-analysis of clinical efficacy and neurovascular regulatory effects.

Researchers reviewed 19 studies involving 1,312 people to evaluate a specific acupuncture treatment for migraines using four key points called "Siguan points." These points include two locations on the hands (Hegu/LI4) and two on the feet (Taichong/LR3). The study compared this acupuncture approach to standard migraine medications and sham (fake) acupuncture.

The results showed that Siguan points-based acupuncture significantly reduced migraine pain intensity, decreased how often migraines occurred, and shortened the number of days people experienced migraines. Patients receiving this treatment were 22% more likely to experience meaningful improvement compared to other treatments. The acupuncture approach also appeared to work by affecting both the brain's pain processing pathways and blood vessel regulation, which are both involved in migraine development.

Importantly, the side effects from acupuncture were similar to conventional treatments, meaning it was just as safe. The evidence quality ranged from moderate to low, suggesting that while results are promising, more high-quality research would strengthen these findings.

For migraine sufferers, this research suggests that acupuncture targeting these specific four points may be an effective alternative or complementary option to medication. The treatment appears to address migraines through multiple mechanisms, potentially offering relief for those who haven't found success with conventional approaches or who prefer non-pharmaceutical options. If you're considering acupuncture for migraines, seek treatment from a licensed acupuncturist trained in traditional point selection and migraine management.

This systematic review with meta-analysis evaluated Siguan points-based acupuncture treatment (bilateral LI4 and LR3) for migraine across 19 RCTs (n=1,312). Primary outcomes demonstrated significant improvements: clinical effective rate (RR 1.22, 95% CI 1.14-1.31), VAS pain reduction (MD -1.11, 95% CI -1.50 to -0.73), and decreased attack frequency (SMD -0.81, 95% CI -1.49 to -0.14). Trial sequential analysis confirmed robustness of primary findings. Adverse events showed no significant differences between SPBAT and control groups (RD -0.04, 95% CI -0.11 to 0.04). GRADE assessment indicated moderate to low certainty evidence. Mechanistic review revealed therapeutic effects through integrated modulation of central pain processing networks and peripheral neurovascular pathways. Clinical implications support SPBAT as a viable migraine management option with comparable safety to conventional pharmacotherapy, though higher-quality trials are needed to strengthen evidence certainty and establish optimal treatment protocols.